How DirectHit® Works

DirectHit examines the amount of certain proteins in a patient’s preserved tumor tissue removed during the original surgery. These proteins are related to how particular drugs work.

DirectHit predicts both resistance and sensitivity to four distinct, commonly prescribed classes of metastatic breast cancer treatments.

Drug Class	Biomarker	Our accuracy when we predict the tumor will be sensitive	Our accuracy when we predict the tumor will be resistant
Antiestrogens	Estrogen Receptor (ER)	94%	100%
Trastuzumab	HER-2	100%	100%
Taxanes/Vinca Alkaloids	Beta Tubulin III	86%	100%
5-FU/Capecitabine	Thymidylate Synthase (TS)	80%	100%

In addition, the following are currently in development: Anthracyclines (topoisomerase IIa), Platinum Drugs (ERCC-1) and Gemcitabine (ribonucleotide reductase).

DirectHit Test results will be available 6 days after the sample is scheduled for testing, and the report will be sent directly to your physician. The Report will provide a value for each specific protein and a recommendation for treatment with the related drug. Please discuss these results carefully with your health care professional

The DirectHit Test Panel for Breast Cancer is performed in CCC Diagnostics’ clinical laboratory, located in Baltimore, MD. CCC Diagnostics, Inc. is licensed by the State of Maryland and registered with CMS (Centers for Medicare and Medicaid Services, an agency of the U.S. Department of Health and Human Services) as administered by CLIA.

DirectHit may only be ordered by your physician or oncologist and its cost may be covered by your insurance. Please check with your carrier.